Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ReGenX partners its NAV AAVs with Dimension Therapeutics

Executive Summary

ReGenX Biosciences LLC (vector technology for use in therapeutics and as research tools) sublicensed rare disease start-up Dimension Therapeutics Inc. preferred exclusive rights to its NAV platform, a collection of recombinant adeno-associated virus (rAAV) vectors including rAAV7, rAAV8, rAAV9, and rAAVrh10. Dimension will use the vectors to deliver rare disease gene treatments, also licensed from ReGenX, for hemophilia A and hemophilia B.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register